Latest Breaking News On - Bon kyoung koo - Page 1 : comparemela.com

 E-Mail IMAGE: Confocal micrographs of mouse small intestine with the Red2Onco technology. With Red2Onco, the oncogenic mutant clones (Red clones), and normal or wild-type clones (Yellow or Cyan clones) can be labeled. view more  Credit: ©Yum/IMBA Studies on cancer are limited by the threshold at which cellular transformations become clinically detectable. However, the very initial phase on the way to malignancy is histologically invisible, as the process originates from one single cell. In this early phase, a so-called seeding cell acquires an initial pro-cancerous mutation, also known as the first oncogenic hit , while being completely surrounded by normal tissue. To overcome the detection barrier, a team of researchers around IMBA group leader Bon-Kyoung Koo and University of Cambridge group leader Professor Benjamin D. Simons developed a laboratory system to dissect the pre-cancerous steps that remained under the radar up until present.

United kingdomBenjamin simonsBon kyoung kooBenjamind simonsSeungmin hanUniversity of cambridgeAustrian federal ministry of scienceGurdon instituteInstitute of molecular biotechnologyAustrian academy of sciencesProfessor benjaminMin kyu yumBone morphogenic proteinMin kyuMolecular biotechnologyVienna biocenter